




ACCESS TO MEDICINES: MILESTONES





ARV ARE FOR LIFE(LONG)



BARRIERS TO ACCESS



COST OF SECOND AND THIRD LINE THERAPIES A CONCERN FOR FUTURE



Source : WHO Global Price reporting mechanism

PRICE COMPARISONS

1st line



TDF/3TC/EFV

2nd line



AZT/3TC+ATV/r

2.7 X
more expensive
than first line

3rd line




RAL+DRV+r+ETV

17.4 X
more expensive
than first line

**no fixed dose
combination**

WIDE PRICE VARIATIONS

TDF+FTC treatment cost comparison
(2013 – 2015 transactions, median cost per person per year US\$)



2016 Political Declaration Commitments

ADDRESS

regulations, policies and practices

that prevent access to safe, efficacious and affordable generic medicines, diagnostics and related health technologies, including by ensuring the

FULL USE

of the existing flexibilities under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)

ENSURE

that intellectual property rights provisions in trade agreements **do not undermine** these existing flexibilities

REDUCE

costs and prices of HIV-related products through use of TRIPS flexibilities, promotion of generic competition and use of voluntary licensing mechanisms

STRENGTHEN

regional and local capacity

to develop, manufacture and deliver quality-assured affordable health products.

UNAIDS 2016-2021 Strategy commitments

1

Promote innovation and ensure availability, quality and affordability

2

Support the use of TRIPS flexibilities and avoid TRIPS-plus provisions

3

Explore new incentive systems for R&D

4

Remove regulatory barriers

UNSG HIGH LEVEL PANEL ON ACCESS TO MEDICINES

1

Further transparency on pricing and patent status

2

Human rights based assessments on access to medicines policy implementation

3

Full use of TRIPS flexibilities

4

New incentives for research and development of health technologies